

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



百仕達控股有限公司*

SINOLINK WORLDWIDE HOLDINGS LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 1168)

**SUPPLEMENTAL ANNOUNCEMENT –
DISCLOSEABLE TRANSACTION
LIMITED PARTNERSHIP AGREEMENT
FOR THE ESTABLISHMENT OF INVESTMENT FUND**

Reference is made to the announcement of Sinolink Worldwide Holdings Limited (the “**Company**”) dated 20 December 2019 (the “**Announcement**”) in respect of the discloseable transaction relating to the establishment of 南京寬平晟諾醫藥投資合夥企業(有限合夥) (Nanjing Kuan Ping Cheng Nuo Yiyao Investment Limited Partner*) (the “**Investment Fund**”) and the subscription of interests therein. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board would like to provide the shareholders and potential investors of the Company with further information relating to the Investment Fund as follows:

INVESTMENT DECISION COMMITTEE OF THE INVESTMENT FUND

Pursuant to the 南京寬平晟諾產業投資管理合夥企業(有限合夥) limited partnership agreement entered into between 寧波梅山保稅港區寬源投資管理有限公司 (as general partner), Shenzhen Shengkechuang (as limited partner) and 寧波梅山保稅港區寬衍投資管理合夥企業(有限合夥) (as limited partner) on 20 December 2019 (“**General Partner Agreement**”), the investment decision committee of the Investment Fund comprise three members, two of which are to be appointed by Kuanping Capital Group and one of which is to be appointed by Shenzhen Shengkechuang. The members of the investment decision committee of the Investment Fund currently comprise Mr. Xiang Jin Yu (“**Mr. Xiang**”), Ms. Li Huihui (“**Ms. Li**”) and Mr. Li Ming (“**Mr. Li**”).

* For identification purpose only

The qualifications of Mr. Xiang, Ms. Li and Mr. Li are as follows:

Mr. Xiang

Mr. Xiang is the Chief Investment Officer and Co-Founder of Syno Capital, a global healthcare and biotech investment firm based in New York City that emphasizes on cross-border collaborations between the United States and China. Mr. Xiang currently serves as director of several venture-backed companies, including LungLife AI, Inc. (a liquid biopsy diagnostics firm in Los Angeles, California, USA) and Orig3n Inc. (a stem cell (iPSC) technology and genetic testing company in Boston, Massachusetts, USA). Mr. Xiang is also a member of the International Advisory Council of the Massachusetts General Hospital and advises the hospital on its global initiatives.

Prior to his current roles, Mr. Xiang served as a Senior Scientist at Schrodinger Inc., a software and consulting firm backed by industry leaders including David E. Shaw and Bill Gates that specializes in computer-aided drug design for biopharma companies. He was responsible for developing next-generation computational tools for rational drug design and various other client drug development programmes. Previously, Mr. Xiang was also part of Genentech's Medicinal Chemistry team, where he participated in numerous leading drug candidate optimization projects.

Mr. Xiang holds a doctoral degree in Molecular Biophysics from Washington University Medical School. His research focus was on the development of cutting-edge computational models to optimize the drug design process. Mr. Xiang authored several publications on this topic in internationally recognized peer-reviewed journals, including Journal of Computational Chemistry and Journal of Chemical Theory and Computation. He graduated Magna Cum Laude from Washington University in St. Louis with bachelor's degrees in Biomedical Engineering, Economics, Mathematics and Computer Science.

Ms. Li

Ms. Li is the Founding Partner and Chief Executive Officer of Kuanping Capital Group and held 99.5% of the issued share capital of its investment management company, 寧波梅山保稅港區寬源投資管理有限公司, which was incorporated in March 2016 and holds the Fund Management License granted by the Asset Management Association of China. Ms. Li has more than 10 years of experience in healthcare investment, merger and acquisition, corporate strategy and capital markets activities. Ms. Li currently oversees the general business of Kuanping Capital Group, including investment, portfolio management, risk control and mid-to-back office operations.

Prior to her current position, Ms. Li served as the Vice President of 3SBio Inc. ("3SBio"), a company listed on the Stock Exchange (stock code:1530), and was in charge of the 3SBio's capital markets activities and corporate investments, including its Hong Kong initial public offering process. During her time at 3SBio, she completed several strategic acquisitions, such as 3SBio Guojian, Shenzhen Sciprogene, and Zhejiang Wansheng.

Before joining 3SBio, Ms. Li was a core member of CITIC PE healthcare team. Prior to that, Ms. Li was a Consultant at Bain & Company Greater China and served leading Chinese and international private equity fund managers.

Ms. Li holds a master's degree in management from Shanghai University of Finance and Economics.

Mr. Li

Mr. Li is a Partner of Kuanping Capital Group. He is currently in charge of the investment and research activities of Kuanping Capital Group. Mr. Li has more than 10 years of experience in healthcare investment, portfolio management and corporate strategy.

Prior to his current position, Mr. Li was a founding member of Hillhouse Capital Group's healthcare private equity team, in charge of investments in medical technology and services sectors. He led the privatization deal of WuXi AppTec, a global pharmaceutical, biopharmaceutical and medical device company.

Mr. Li was the co-founder of FountainVest Partners' healthcare team. He led multiple buyout transactions, including Kehua Bio and Chang'an Hospital.

Prior to that, Mr. Li worked at CITIC PE healthcare team and Bain & Company.

Mr. Li holds a bachelor's degree in Mathematics and Economics from Peking University.

To the best of the Directors' knowledge, information and belief, after having made all reasonable enquiries, the Investment Fund currently has no proposed investment targets.

GENERAL PARTNER OF THE INVESTMENT FUND

Credentials of the founding partners of the General Partner

Although the General Partner, being the general partner and executive partner of the Investment Fund, was established on 30 May 2019 and does not have a significant investment performance track record, based on the credentials of the founding partners of the General Partner, Ms. Li and Mr. Li, in particular, (i) their experience in healthcare investment, corporate strategy, merger and acquisition and capital markets activities, and (ii) their track record in completing equity investments, the Directors were of the view that the founding partners of the General Partner possess relevant investment performance track records so as to enable the Investment Fund to capture investment opportunities and further diversify the Group's investment portfolio. For details of the credentials of each of Ms. Li and Mr. Li, please refer to the section headed "Investment Decision Committee of the Investment Fund" above.

Ultimate beneficial owners of the General Partner

To the best of the Directors' knowledge, information and belief, after having made all reasonable enquiries, the General Partner is held as to 1.0% and 99.0% by 寧波梅山保稅港區寬源投資管理有限公司 (as general partner) and 寧波梅山保稅港區寬衍投資管理合夥企業(有限合夥) (as limited partner), respectively, as at the date of this announcement.

Pursuant to the General Partner Agreement, upon the necessary registrations of the Investment Fund with the relevant authorities in the PRC, the General Partner will be held as to 1.0%, 29.0% and 70.0% by 寧波梅山保稅港區寬源投資管理有限公司 (as general partner), Shenzhen Shengkechuang (as limited partner) and 寧波梅山保稅港區寬衍投資管理合夥企業(有限合夥) (as limited partner), respectively.

As at the date hereof, to the best of the Directors' knowledge, information and belief, after having made all reasonable enquiries:

- (i) 寧波梅山保稅港區寬源投資管理有限公司 is held as to 99.5% by Ms. Li and 0.5% by Mr. Li;
- (ii) Shenzhen Shengkechuang is held as to 1.0% by Mr. Hu Yonghua and 99.0% by 加德裕信息諮詢(深圳)有限公司. 加德裕信息諮詢(深圳)有限公司 is wholly-owned by Anytime Limited, which is in turn wholly-owned by Powerjoy Limited. Powerjoy Limited is held as to 70.0% by Mr. Xiang Ya Bo and 30.0% by Ms. Wu Hang Wa (being the spouse of Mr. Xiang Ya Bo); and
- (iii) 寧波梅山保稅港區寬衍投資管理合夥企業(有限合夥) is held as to 99.0% by Ms. Li and 1.0% by 寧波梅山保稅港區思邈投資管理有限公司. 寧波梅山保稅港區思邈投資管理有限公司 is held as to 99.0% and 1.0% by Ms. Li and Mr. Li, respectively.

To the best of the Directors' knowledge, information and belief, after having made all reasonable enquiries, save as disclosed in this announcement and save for (i) Shenzhen Shengkechuang (being an associate of Mr. Xiang Ya Bo, who is an executive Director, the chairman of the Board and chief executive officer of the Company) which owns 29% in the General Partner (as limited partner); and (ii) Mr. Xiang (the son of Mr. Xiang Ya Bo) being a legal representative of Shenzhen Shengkechuang, and (iii) the partnership relationship specified in the Limited Partnership Agreement,

- (i) the General Partner and the Limited Partners (other than Shenzhen Sinolink) and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons; and

- (ii) there are no relationships, directly or indirectly, between the General Partner and each of the Limited Partners.

By order of the Board
Sinolink Worldwide Holdings Limited
XIANG Ya Bo
Chairman and Chief Executive Officer

Hong Kong, 21 January 2020

As at the date of this announcement, the Board comprises Mr. Xiang Ya Bo (Chairman of the Board and Chief Executive Officer) and Mr. Chen Wei as executive Directors; Mr. Ou Yaping, Mr. Ou Jin Yi Hugo and Mr. Tang Yui Man Francis as non-executive Directors; and Mr. Tian Jin, Dr. Xiang Bing and Mr. Xin Luo Lin as independent non-executive Directors.